Pathway to obesity: Study links TMAO-producing gut bacteria to obesity risk
The way bacteria in our gut metabolise the foods we eat could have a strong impact on obesity risk, while blocking certain pathways could lead to prevention, say researchers.
Intellirod Spine™ Acquires Cleveland Clinic IP
Intellirod Spine, the spinal implant company developing disposable and implantable wireless RFID sensor technology for monitoring spinal rod strains, secured additional equity financing from new and existing investors led by the OhioHealth Innovation Development Fund and Queen City Angel First Fund V. Funds will be used to reach key milestones toward the commercialization of the company’s sensor technologies and related lumbar fusion implants.
OncoSynergy and Infuseon Therapeutics Partner to Combat Glioblastoma
Infuseon Therapeutics and OncoSynergy have entered into a strategic alliance to test an investigational glioblastoma therapeutic, OS2966, in combination with a novel delivery device, the Cleveland Multiport CatheterTM. Glioblastoma is the most common and malignant primary brain tumor. Despite a median survival of merely 12 months, there have been only four FDA approved therapies and no improvement in overall survival in nearly three decades. This unmet need is driven in part by the inability of most chemotherapies and particularly biologics to penetrate the blood-brain-barrier.
ClearFlow, Inc. Receives FDA Clearance for FlowGlide Technology for Cardiac Surgery Patients
ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted 510[k] clearance for the company’s proprietary FlowGlide™ Active Clearance Technology® System.
The FlowGlide™ System is the next generation of ClearFlow’s Active Clearance Technology that prevents or reduces chest drains from occluding with clot, which can lead to retained blood around the heart and lungs. The composite of drainage-related complications that are detrimental to outcomes after cardiothoracic surgery and that may require early or late intervention to remediate is known as Retained Blood Syndrome (RBS). These clinical complications have significant economic consequences, including higher costs of care for patients, hospitals, and society at large.
Infuseon Therapeutics Earns FDA Clearance for Novel Central Nervous System Delivery Device
Infuseon Therapeutics’ novel central nervous system deliver device has received FDA 510(k) clearance as a therapeutic delivery device.
Infuseon Therapeutics’ Cleveland Multiport CatheterTM (CMC), a multiport convection-enhanced delivery catheter, was designed by neurosurgeon Michael Vogelbaum, MD, PhD, from Cleveland Clinic’s Brain Tumor and NeuroOncology Center and Department of Neurosurgery, to effectively deliver therapeutics to patients at the site of their disease. FDA clearance was granted in March 2017.
Cleveland Clinic Brings The Promise of Telemedicine To Reality
Several people I know who have retired to Florida in recent years still return to the New York area a couple of times a year just to see their doctors. In the majority of cases, these are simply routine follow-ups. But in the era of expanding healthcare technology, smartphones, and tablets, this all seems pretty inefficient, not to mention expensive. Why not just reach out to your practitioner remotely? That’s been the promise of telemedicine for several decades. Now institutions like the Cleveland Clinic are moving it from trial into practice. At the recent Techonomy Health Conference in New York, we had the opportunity to sit down with Dr. Brian Donley, Chief of Staff of the Cleveland Clinic, to speak about their telemedicine program.
Cleveland Clinic-led Study Finds That New Blood Test is More Accurate in Predicting Overall Risk of Prostate Cancer than Standard Prostate-Specific Antigen (PSA)
A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures – distinguishing cancer from benign conditions, and identifying patients with high-risk disease.
ERT Acquires Imaging Solution from Cleveland Clinic
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced the acquisition of ImageIQ, originally established as Cleveland Clinic’s Biomedical Imaging and Analysis Center. The acquisition enables ERT to offer advanced, end-to-end clinical trial imaging analysis using best-in-class technology that delivers compliant data for use in clinical development.
Cleveland HeartLab Adds Two Additional Patents to its Extensive Intellectual Property Position for the Myeloperoxidase (MPO) test, a key predictor of Major Cardiac Events
Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that two new patents for Myeloperoxidase (MPO) testing have been issued: U.S. Patent No. 9,581,597 and U.S. Patent No. 9,612,242. Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including these two newly issued patents. Originally discovered and developed at the Cleveland Clinic, MPO testing has been recognized in over 100 peer-reviewed publications as a key measure of vascular inflammation, which plays a key role in CVD and cardiovascular events. These new patents will add to Cleveland HeartLab's already existing portfolio of intellectual property rights, which includes 26 issued patents and an additional 15 pending patent applications.
Cleveland Clinic names two new leaders for commercialization divisions
The Cleveland Clinic recently appointed new leaders to its divisions that commercialize medical innovations while creating jobs and attracting talent to Cleveland.